Archives of Dermatological Research最新文献

{"title":"Investigating dermatology content on TikTok and its potential impact on URiM medical students’ specialty choice","authors":"Sheehan Parvez,&nbsp;Courtney R. Schadt,&nbsp;Jeffrey P. Callen","doi":"10.1007/s00403-025-04384-8","DOIUrl":"10.1007/s00403-025-04384-8","url":null,"abstract":"<div><p>Social media platforms like TikTok influence public and professional perceptions of medical specialties. Dermatology-related content on TikTok is thought to present a limited view of the specialty, potentially underrepresenting academic dermatologists, subspecialties, and dermatologists of color. This skewed portrayal may impact medical students’ specialty choices, particularly those from underrepresented minority (URiM) backgrounds. A cross-sectional content analysis of dermatology-related TikTok videos was conducted. Using a virtual private network, the top 186 most-liked videos under the search terms “Dermatology,” “Dermatologist,” “Derm,” and “DermTok” were identified and analyzed. Videos were categorized by dermatologist race/ethnicity, practice setting, gender, content type (medical vs. cosmetic dermatology), and subspecialty representation. Most videos (95.2%) featured private practice dermatologists, with academic dermatologists significantly underrepresented (4.8%). Content included cosmetic (38.7%) and medical dermatology (61.3%), but no videos (0%) featured subspecialties such as dermatologic surgery, pediatric dermatology, or dermatopathology. Additionally, 69.4% of videos featured a dermatologist not of skin of color (Fitzpatrick skin type I–III). The portrayal of dermatology on TikTok is dominated by private practice dermatologists, with minimal representation of subspecialties and skin of color dermatologists. This narrow depiction may reinforce existing disparities and deter URiM medical students from pursuing dermatology. Increasing diversity in clinician representation and subspecialty exposure on social media could foster a more inclusive and accurate depiction of the field, supporting efforts to enhance workforce diversity.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145168846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing U.S. public health awareness and laboratory readiness for Trichophyton Indotineae","authors":"Anna Catinis,&nbsp;Nisa Ilsin,&nbsp;Haleigh Stafford,&nbsp;Theodore Rosen","doi":"10.1007/s00403-025-04382-w","DOIUrl":"10.1007/s00403-025-04382-w","url":null,"abstract":"<div><p><i>Trichophyton indotineae</i> is a highly transmissible, multidrug-resistant dermatophyte that presents a growing international public health concern. Accurate diagnosis often requires molecular testing, yet many laboratories lack the tools or awareness to identify it. To evaluate diagnostic readiness in the United States, we surveyed public health mycologists and microbiologists across all 50 states, Puerto Rico, American Samoa, and the Centers for Disease Control and Prevention (CDC). The survey assessed familiarity with <i>T. indotineae</i> and access to speciation and resistance testing. We received 45 responses (86.5% response rate), revealing that 71% of respondents were either unfamiliar with <i>T. indotineae</i> or unsure if they had encountered it. Only four public health laboratories reported the capability to identify <i>T. indotineae</i> or perform antifungal susceptibility testing. Most indicated they would refer unidentified dermatophyte samples to the CDC, despite the agency confirming it does not currently offer CLIA-certified testing for this pathogen. These findings highlight major gaps in awareness and testing capacity across the U.S. public health system. Improving diagnostic access and provider education will be critical for effective surveillance and management of this emerging fungal threat.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145168848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The adverse cosmetic effects of GLP-1 receptor agonists on the face, body, and hair: a narrative review","authors":"Megan Hoang,&nbsp;Fatima N. Mirza,&nbsp;Tatiana Abrantes,&nbsp;Pavane L. Gorrepati,&nbsp;Tiffany J. Libby","doi":"10.1007/s00403-025-04379-5","DOIUrl":"10.1007/s00403-025-04379-5","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145168050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiota, mind, and skin: bridging the Gut-Brain-Skin axis in psychodermatology","authors":"Ameena Ali,&nbsp;Mohammad Jafferany","doi":"10.1007/s00403-025-04385-7","DOIUrl":"10.1007/s00403-025-04385-7","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of facility volume on overall survival among patients with skin cancer undergoing palliative treatment","authors":"Hamail Iqbal,&nbsp;Aman M. Patel,&nbsp;Amar D. Desai","doi":"10.1007/s00403-025-04387-5","DOIUrl":"10.1007/s00403-025-04387-5","url":null,"abstract":"<div><p>Treatment at high-volume facilities (HVFs) has been associated with improved survival of patients with skin cancer undergoing curative treatment. The influence of facility volume on overall survival (OS) in such patients undergoing palliative treatment is unknown. To investigate the impact of facility volume on OS in patients with skin cancer undergoing palliative treatment, the 2004 to 2018 National Cancer Database was queried for patients with skin cancer undergoing palliative treatment (N = 5,510). Patients were stratified based on facility volume percentile. Multivariable binary logistic and Cox proportional hazards regression models were implemented. Of 909 facilities, 464 (51.0%), 217 (23.9%), 127 (14.0%), 67 (7.4%), and 34 (3.7%) had volume &lt; 20th, 20-40th, 40-60th, 60-80th, and ≥ 80th percentiles, respectively. Patients with Medicaid (aHR 0.54, 95% CI 0.38–0.76, <i>P</i> &lt; 0.001), a Charlson-Deyo comorbidity score of 1 (aHR 0.68, 95% CI 0.53–0.88, <i>P</i> = 0.003), receiving palliative radiotherapy alone (aHR 0.70, 95% CI 0.51–0.96, <i>P</i> = 0.027), and a tumor stage &gt; 1 were less likely to receive palliative treatment at a facility with volume ≥ 80th percentile. 5-year OS of patients undergoing palliative therapy at facilities with volume &lt; 20th, 20-40th, 40-60th, 60-80th, and ≥ 80th percentile was 9%, 8%, 11%, 12%, and 20%, respectively (<i>P</i> &lt; 0.001). Facilities with volume ≥ 70th percentile were associated with higher 5-year OS (<i>P</i> &lt; 0.001). Undergoing palliative treatment at HVFs is associated with higher OS in patients with skin cancer. The survival benefit derived from HVFs should be contextualized with other patient and facility factors affecting access of palliative services. Level of Evidence: 4</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04387-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Kligman’s formula in the treatment of melasma: a systematic review and meta analysis","authors":"Sara M. Alghamdi,&nbsp;Mohammed A. Alahmadi,&nbsp;Ruba M. Alghanmi,&nbsp;Dareen K. Bajamaan,&nbsp;Abdullah S. Algarni","doi":"10.1007/s00403-025-04369-7","DOIUrl":"10.1007/s00403-025-04369-7","url":null,"abstract":"<div><p>Melasma is a chronic pigmentary disorder with significant therapeutic challenges. Kligman’s formula, a triple combination of hydroquinone, tretinoin, and fluocinolone acetonide, has been widely used due to its efficacy in reducing hyperpigmentation. However, its long-term effectiveness and comparative advantage over alternative treatments remain unclear. This systematic review and meta-analysis assess the efficacy and safety of Kligman’s formula in melasma treatment by analyzing changes in modified Melasma Area and Severity Index (mMASI) and Melasma Area and Severity Index (MASI) scores. A systematic search of PubMed, Google Scholar, Web of Science, Wiley, EBSCO, and OVID identified randomized controlled trials and comparative studies evaluating Kligman’s formula in melasma management. Studies reporting baseline and maintenance phase mMASI and MASI scores were included. Meta-analysis was performed using a random-effects model, and heterogeneity was assessed using the I² statistic. The pooled analysis included studies from Iran, Brazil, the USA, and India, with diverse participant characteristics. At baseline, the difference in mMASI scores between intervention and control groups was not significant (Estimate: 0.209; 95% CI −0.861 to 1.279; <i>P</i> = 0.702). At the maintenance phase, the difference in mMASI scores remained insignificant (Estimate: −0.793; 95% CI −2.535 to 0.949; <i>P</i> = 0.372), as did MASI scores (Estimate: 0.421; 95% CI −0.346 to 1.188; <i>P</i> = 0.282). Kligman’s formula does not provide a statistically significant advantage over alternative treatments in reducing melasma severity. High heterogeneity across studies suggests that genetic, environmental, and methodological factors affect outcomes. Further well-designed trials are needed to optimize melasma management and explore alternative therapies with improved efficacy and safety.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are the mechanisms underlying atopic dermatitis (AD) a risk factor for alopecia areata (AA)?","authors":"Fatemeh Siahmarzkouhi,&nbsp;Yasaman Asadikalbibaki,&nbsp;Razieh Dindarlou,&nbsp;Javid Ashtarimahini","doi":"10.1007/s00403-025-04367-9","DOIUrl":"10.1007/s00403-025-04367-9","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous histiocytoses: a clinical and histopathological series of 25 cases","authors":"Sera Nur Yucesoy,&nbsp;Tumay Ak,&nbsp;Betül Altuntaş Keskin,&nbsp;Koray Temiz,&nbsp;Elif Cansel Gümüş,&nbsp;Ayşe Mine Önenerk,&nbsp;Övgü Aydın Ülgen,&nbsp;Burhan Engin","doi":"10.1007/s00403-025-04381-x","DOIUrl":"10.1007/s00403-025-04381-x","url":null,"abstract":"<div><p>Cutaneous histiocytoses are a heterogeneous group of disorders characterized by histiocytic proliferation within the skin, broadly classified into Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (non-LCH). The clinical presentation varies widely, making histopathological and immunohistochemical analyses essential for accurate diagnosis. This study aims to evaluate the clinical, histopathological, and immunohistochemical features of patients diagnosed with cutaneous histiocytosis in a single-center cohort. We retrospectively analyzed 25 patients diagnosed with cutaneous histiocytosis between 2000 and 2022. Demographic characteristics, clinical presentation, lesion distribution, systemic involvement, histopathology, and immunohistochemical findings were assessed. Statistical analyses were performed using IBM SPSS Statistics 21.0. Of the 25 patients, 19 were diagnosed with LCH and 6 with non-LCH. The median age was 7 years (Q1-Q3: 2–29 years), and the median symptom duration was 4.5 months (Q1-Q3: 2–12 months). The most common LCH presentation was seborrheic dermatitis-like lesions (9/19 patients), predominantly on the scalp, with CD1a (+) and Langerin (+) histiocytic infiltration. Among non-LCH cases, three were juvenile xanthogranuloma (JXG), one was generalized eruptive histiocytosis (GEH), one was Erdheim-Chester disease (ECD), and and one was unclassified non-LCH. Systemic disease was observed in 28% of patients (7/25), including hepatosplenomegaly (3 patients), lytic bone lesions (3 patients), and pontine lesions with lung cysts (1 patient). This study underscores the diverse clinical and histopathological spectrum of cutaneous histiocytoses, emphasizing the importance of immunohistochemistry in distinguishing LCH from non-LCH subtypes. The high frequency of seborrheic dermatitis-like lesions in LCH suggests that persistent or treatment-resistant cases should prompt histopathological evaluation.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologist prescribing patterns for androgenetic alopecia therapies among Medicare beneficiaries","authors":"Q. Wilton Sun,&nbsp;William E. Damsky,&nbsp;Jeffrey M. Cohen","doi":"10.1007/s00403-025-04374-w","DOIUrl":"10.1007/s00403-025-04374-w","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Granulomatous reaction to hyaluronic acid filler following colonoscopy with colonic biopsy","authors":"G. Ege Eskibozkurt,&nbsp;Michelle S. Lee,&nbsp;Farhana Jan,&nbsp;Hye Jin Chung","doi":"10.1007/s00403-025-04373-x","DOIUrl":"10.1007/s00403-025-04373-x","url":null,"abstract":"<div>\u0000 \u0000 <p>Late-onset inflammatory reactions to hyaluronic acid (HA) fillers are rare but recognized complications, often associated with recent dental procedures, viral illness, and vaccination. We report the first possible case of late-onset granulomatous reaction to HA filler following colonoscopy with colonic biopsy. A 78-year-old woman abruptly developed multiple erythematous nodules on the submental chin, upper cutaneous lip, and cheeks one week after colonoscopy with biopsy. She had received HA filler injections to the chin, perioral region, cheeks, and jawline six months earlier. Skin biopsy confirmed granulomatous inflammation surrounding HA filler material. The patient was treated with a prednisone taper and doxycycline, resulting in marked improvement within one month and near-complete resolution by three months. This case highlights gastrointestinal procedures as a potential yet previously unreported trigger for late-onset filler reactions. Three potential mechanisms linking the gastrointestinal procedure to the late-onset filler reaction include: (1) transient bacteremia following mucosal disruption, (2) reactivation of dormant biofilm at filler sites, and (3) immune dysregulation due to bowel-preparation-induced dysbiosis. Host-specific factors, such as genetic predisposition including certain HLA haplotypes (e.g., HLA-B08, HLA-DRB103), and product-related factors, such as cumulative exposure to multiple filler types in the same facial region over time, may further modulate the risk and severity of delayed inflammatory reactions. Further research is warranted to elucidate the roles of systemic immune shifts and microbiome disruption in filler immunogenicity.</p>\u0000 </div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}